- Home
- DALN vs IGC Comparison
DALN vs IGC Comparison
Compare DALN & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- IGC
- Stock Information
- Founded
- DALN 1954
- IGC 2005
- Country
- DALN United States
- IGC United States
- Employees
- DALN N/A
- IGC N/A
- Industry
- DALN Newspapers/Magazines
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- DALN Consumer Discretionary
- IGC Health Care
- Exchange
- DALN Nasdaq
- IGC Nasdaq
- Market Cap
- DALN 29.3M
- IGC 26.9M
- IPO Year
- DALN 2008
- IGC N/A
- Fundamental
- Price
- DALN $5.65
- IGC $0.35
- Analyst Decision
- DALN
- IGC Strong Buy
- Analyst Count
- DALN 0
- IGC 2
- Target Price
- DALN N/A
- IGC $3.63
- AVG Volume (30 Days)
- DALN 101.6K
- IGC 222.5K
- Earning Date
- DALN 11-12-2024
- IGC 11-12-2024
- Dividend Yield
- DALN 11.32%
- IGC N/A
- EPS Growth
- DALN N/A
- IGC N/A
- EPS
- DALN N/A
- IGC N/A
- Revenue
- DALN $128,286,000.00
- IGC $1,183,000.00
- Revenue This Year
- DALN N/A
- IGC N/A
- Revenue Next Year
- DALN N/A
- IGC $13.57
- P/E Ratio
- DALN N/A
- IGC N/A
- Revenue Growth
- DALN N/A
- IGC N/A
- 52 Week Low
- DALN $2.98
- IGC $0.25
- 52 Week High
- DALN $6.47
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- DALN 54.61
- IGC 42.76
- Support Level
- DALN $4.95
- IGC $0.33
- Resistance Level
- DALN $6.23
- IGC $0.42
- Average True Range (ATR)
- DALN 0.54
- IGC 0.02
- MACD
- DALN -0.01
- IGC -0.00
- Stochastic Oscillator
- DALN 38.81
- IGC 32.14
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.